Generic Eskata Availability
Last updated on Apr 10, 2025.
Eskata is a brand name of hydrogen peroxide topical, approved by the FDA in the following formulation(s):
ESKATA (hydrogen peroxide - solution;topical)
-
Manufacturer: ACLARIS
Approval date: December 14, 2017
Strength(s): 40% (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eskata. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Peroxide formulations and methods and applicators for using the same
Patent 10,098,910
Issued: October 16, 2018
Inventor(s): Shanler Stuart D. & Powala Christopher & Phillips Christopher & Beger Brian & Greenaway Evans Charles Rodney & Lim Sian Tiong & Brown Marc Barry & Botta Michael A. & Nagler Thomas
Assignee(s): ACLARIS THERAPEUTICS, INC.Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
Patent expiration dates:
- April 21, 2035✓✓
- April 21, 2035
-
Peroxide formulations and methods and applicators for using the same
Patent 10,493,103
Issued: December 3, 2019
Inventor(s): Shanler Stuart D. & Powala Christopher & Phillips Christopher & Beger Brian & Greenaway Evans Charles Rodney & Lim Sian Tiong & Brown Marc Barry & Botta Michael A. & Nagler Thomas
Assignee(s): Aclaris Therapeutics, Inc.Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
Patent expiration dates:
- April 21, 2035✓
- April 21, 2035
-
Peroxide formulations and methods and applicators for using the same
Patent 10,729,720
Issued: August 4, 2020
Inventor(s): Shanler Stuart D. & Powala Christopher & Phillips Christopher & Beger Brian & Greenaway Evans Charles Rodney & Lim Sian Tiong & Brown Marc Barry & Botta Michael A. & Nagler Thomas
Assignee(s): ACLARIS THERAPEUTICS, INC.Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
Patent expiration dates:
- April 21, 2035✓
- April 21, 2035
-
Peroxide formulations and methods and applicators for using the same
Patent 9,675,639
Issued: June 13, 2017
Inventor(s): Shanler Stuart D. & Powala Christopher & Phillips Christopher & Beger Brian & Greenaway Evans Charles Rodney & Lim Sian Tiong & Brown Marc Barry & Botta Michael A. & Nagler Thomas
Assignee(s): ACLARIS THERAPEUTICS, INC.Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
Patent expiration dates:
- July 4, 2035✓✓
- July 4, 2035
-
Peroxide formulations and methods and applicators for using the same
Patent 9,980,983
Issued: May 29, 2018
Inventor(s): Shanler Stuart D. & Powala Christopher & Phillips Christopher & Beger Brian & Greenaway Evans Charles Rodney & Lim Sian Tiong & Brown Marc Barry & Botta Michael A. & Nagler Thomas
Assignee(s): ACLARIS THERAPEUTICS, INC.Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
Patent expiration dates:
- April 21, 2035✓
- April 21, 2035
More about Eskata (hydrogen peroxide topical)
- Eskata consumer information
- Check interactions
- Compare alternatives
- Reviews (10)
- Side effects
- Dosage information
- FDA approval history
- Drug class: topical anti-infectives
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.